Schlieren (Zurich), Switzerland, January 8, 2018
Kuros Biosciences Expands License Agreement with Checkmate
Kuros (SIX: KURN) announced today that it has amended its exclusive license agreement, which was originally signed in 2015, that grants Checkmate Pharmaceuticals Inc., Cambridge, MA, USA ("Checkmate") access to Kuros' clinically validated product candidate CYT003 as well as its VLP platform and to technology related to oligonucleotide synthesis.
The amendment extends the field from oncology to all indications and broadens the range of product candidates covered. In exchange for the amendment of the license, Kuros receives an upfront payment and is eligible for additional milestone payments and royalties.
"We are excited about the amendment of the existing agreement with Checkmate and continue to believe that Checkmate is well positioned to advance treatment options for patients", commented Joost de Bruijn, CEO of Kuros. "The Checkmate team is pleased to obtain these rights to Kuros' VLP platform, which we believe has a great deal of potential for further clinical development", affirmed Art Krieg, CEO of Checkmate.
Provider | Channel | Contact | ||
---|---|---|---|---|
Tensid EQS Ltd., Switzerland www.tensid.ch |
newsbox.ch www.newsbox.ch |
Provider/Channel related enquiries marco@tensid.ch +41 41 763 00 50 |